Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
World Journal of Gastrointestinal Pathophysiology · 10.09.2019 · 10 (2) · 17-28
DOI: 10.4291/wjgp.v10.i2.17 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Gastrointestinal Pathophysiology, erschienen am 10.09.2019. Verfasst von Tsutomu Nishida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Toyonaka Municipal Hospital, Osaka 560-8565, Japan, tnishida.gastro@gmail.com. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The indications of immune checkpoint inhibitors (ICPIs) for cancer treatment have rapidly expanded, and their use is increasing in clinical settings worldwide. Despite the considerable clinical benefits of ICPIs, frequent immune-related adverse events (irAEs) have become nonnegligible concerns. Among irAEs, ICPI-induced colitis/diarrhea is frequent and recognized not only by oncologists but also by gastroenterologists or endoscopists. The endoscopic findings show similarity to those of inflammatory bowel disease to a certain extent, particularly ulcerative colitis, but do not seem to be identical. The pathological findings of ICPI-induced colitis may vary among drug classes. They show acute or chronic inflammation, but it may depend on the time of colitis suggested by colonoscopy, including biopsy or treatment intervention. In the case of chronic inflammation determined by biopsy, the endoscopy findings may overlap with those of inflammatory bowel disease. Here, we provide a comprehensive review of ICPI-induced colitis based on clinical, endoscopic and pathologic findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Toyonaka Municipal Hospital, Osaka 560-8565, Japan, tnishida.gastro@gmail.com.
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
- Department of Pathology, Toyonaka Municipal Hospital, Osaka 560-8565, Japan.
Zitieren
APA
Nishida, T., Iijima, H., & Adachi, S. (2019). Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 10(2), 17-28. https://doi.org/10.4291/wjgp.v10.i2.17
Vancouver
Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology. 2019;10(2):17-28. doi:10.4291/wjgp.v10.i2.17
BibTeX
@article{Nishida2019,
author = {Nishida, Tsutomu and Iijima, Hideki and Adachi, Shiro},
title = {Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings},
journal = {World Journal of Gastrointestinal Pathophysiology},
year = {2019},
volume = {10},
number = {2},
pages = {17--28},
doi = {10.4291/wjgp.v10.i2.17}
}
EUVIMED